Literature DB >> 27614744

A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.

Ahmed Abdel-Razik1, Nasser Mousa2, Hatem Elalfy2, Tarek Fouad Sheta3, Mahmoud Awad3, Mostafa Abdelsalam4, Rania Elhelaly5, Rasha Elzehery5, Nawal S Gouda6, Waleed Eldars6.   

Abstract

BACKGROUND AND AIMS: Ascites with unknown cause remains a diagnostic challenge, which needs novel noninvasive biomarkers for the precise diagnosis. We aimed to evaluate the ascitic fluid and serum C-reactive protein (CRP) and vascular endothelial growth factor (VEGF) as diagnostic markers in the differential diagnosis of malignant and benign ascites.
METHODS: In this prospective work, 315 consecutive patients with ascites were studied. Ascitic fluid and serum levels of CRP and VEGF were evaluated by using an enzyme-linked immunosorbent assay.
RESULTS: Patients were divided into a benign ascites group (group 1) (n = 256) and a malignant ascites group (group 2) (n = 59). Ascitic and serum CRP were significantly elevated in malignant ascites than benign ascites group [5.08 (3.62-6.58) vs. 1.82 (0.64-3.86) ng/ml; P < 0.001 and 12.7 (8.55-17.05) vs. 5.94 (2.57-10.64) ng/ml; P < 0.001], respectively. Ascitic and serum VEGF were significantly increased in malignant ascites than benign ascites patients [0.68 (0.39-0.96) vs. 0.41 (0.25-0.83) ng/ml; P < 0.001 and 0.74 (0.41-1.08) vs. 0.54 (0.23-0.86) ng/ml; P < 0.001], respectively. At a cutoff value of 7.3 and 0.63 ng/ml, serum CRP and VEGF had specificity (77.3 and 89.5 %) and sensitivity (83.1 and 94.9 %) for detecting malignant ascites [area under the curve (AUC) 0.821, 0.921], respectively. At a cutoff value of 2.5 and 0.57 ng/ml, ascitic CRP and VEGF had specificity (81.6 and 85.5 %) and sensitivity (84.7 and 91.5 %) for detecting malignant ascites (AUC 0.842, 0.894), respectively.
CONCLUSION: Elevated ascitic fluid and serum CRP and VEGF values were related to the malignant ascites.

Entities:  

Keywords:  C-reactive protein; Malignant ascites; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2017        PMID: 27614744     DOI: 10.1007/s12029-016-9873-x

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  38 in total

Review 1.  Malignant ascites.

Authors:  S L Parsons; S A Watson; R J Steele
Journal:  Br J Surg       Date:  1996-01       Impact factor: 6.939

2.  Role of cholesterol determination in ascitic fluid analysis.

Authors:  Alexander L Gerbes; Dieter Jüngst
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

3.  Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012.

Authors:  Bruce A Runyon
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

Review 4.  Measuring the accuracy of diagnostic systems.

Authors:  J A Swets
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice.

Authors:  J Yoneda; H Kuniyasu; M A Crispens; J E Price; C D Bucana; I J Fidler
Journal:  J Natl Cancer Inst       Date:  1998-03-18       Impact factor: 13.506

7.  Carcinoembryonic antigen assay of ascites and detection of malignancy.

Authors:  M S Loewenstein; R A Rittgers; A E Feinerman; H Z Kupchik; B R Marcel; R S Koff; N Zamcheck
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

8.  Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

Authors:  Aristotelis Bamias; Vasiliki Koutsoukou; Evangelos Terpos; Marinos L Tsiatas; Christina Liakos; Ourania Tsitsilonis; Alexandros Rodolakis; Zannis Voulgaris; G Vlahos; Theocharis Papageorgiou; G Papatheodoridis; A Archimandritis; A Antsaklis; M A Dimopoulos
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

9.  Role of VEGF and CD44v6 in differentiating benign from malignant ascites.

Authors:  Wei-Guo Dong; Xiao-Min Sun; Bao-Ping Yu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 10.  A systematic review of the association between circulating concentrations of C reactive protein and cancer.

Authors:  Katriina Heikkilä; Shah Ebrahim; Debbie A Lawlor
Journal:  J Epidemiol Community Health       Date:  2007-09       Impact factor: 3.710

View more
  1 in total

1.  Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.

Authors:  Matteo Bonatti; Riccardo Valletta; Giulia A Zamboni; Fabio Lombardo; Maria Senoner; Mariachiara Simioni; Guenther Schifferle; Giampietro Bonatti
Journal:  Eur Radiol       Date:  2019-01-14       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.